22 hrs ago
Novo Nordisk Targets Blockbuster Launches Amid Obesity-Drug Patent Concerns
Novo Nordisk makes medicines for diabetes and weight loss.
It wants to release more than five very successful new medicines by 2030.
The company is preparing because patents protecting its semaglutide medicines will expire in the early 2030s.
It plans to launch CagriSema early next year.
Other medicines, including cagrilintide and a stronger version of CagriSema, are planned for 2028.
Novo also wants to make enough medicine for many more patients and expand its pills.
Company leaders are confident about future sales.
However, investors worried about prices and the company’s business deals, and its shares fell.
Novo Nordisk aims to launch more than five blockbuster drugs by 2030.
The company expects more than 150 billion Danish crowns in pipeline sales by 2035.
CagriSema is targeted for launch early next year, with additional obesity treatments planned through 2028.
Novo aims to reach more than 60 million patients and increase manufacturing capacity tenfold by 2030.
The company said restructuring-related departures have reached 13,000 employees, including 9,000 initial cuts and 4,000 later exits.
- Who
- Novo Nordisk and its CEO Mike Doustdar.
- What
- The company announced plans for more than five blockbuster drug launches by 2030 and outlined future sales, manufacturing, and restructuring targets.
- Where
- The plans were presented at Novo Nordisk’s Capital Markets Day in London.
- When
- The targets extend through 2030 and 2035; CagriSema is targeted for launch early next year, with other treatments planned for 2028.
- Why
- Novo is preparing for patent expirations affecting semaglutide, the active ingredient in its Ozempic and Wegovy franchises, in the early 2030s.
Novo Nordisk’s Growth Outlook
Investor Concerns
Future drug pipeline
Novo Nordisk’s Growth Outlook
Management said new obesity treatments, oral medicines, and more than five potential blockbuster launches can support growth through 2030 and beyond.
Investor Concerns
Analysts questioned whether the company’s pipeline and dealmaking strategy would offset the challenges posed by looming semaglutide patent expirations.
Pricing power
Novo Nordisk’s Growth Outlook
Novo highlighted its sales ambitions, including more than 150 billion Danish crowns in pipeline sales by 2035 and strong demand for its oral Wegovy pill.
Investor Concerns
Investors questioned the company’s pricing power, contributing to a share-price decline of as much as 9%.
Key facts
- 2030 drug target
- More than five blockbuster launches
- 2035 pipeline sales target
- More than 150 billion Danish crowns, or $23 billion
- Patient reach target
- More than 60 million patients globally by 2030
- Manufacturing target
- Tenfold expansion to supply 15 million patients with oral obesity therapies by 2030
- Planned launches
- CagriSema early next year; standalone cagrilintide and high-dose CagriSema in 2028
- Oral pipeline
- At least five oral assets in clinical trials before the end of the year
- Restructuring departures
- 13,000 employees in total
- Share-price reaction
- Shares fell as much as 9%
Sources
Related news
China Enters Race for Next Generation Weight-Loss Drugs
Lupin Reassesses GLP-1 Market as It Develops New Treatments
Novo Nordisk and Eli Lilly Sued Over Vision Loss Claims
China’s Weight-Loss Drug Market Attracts Big Pharma Advertising Push
Mounjaro Becomes India’s Top-Selling Drug Amid GLP-1 Shift
Ozempic, Wegovy and Zepbound Makers Face US Blindness Lawsuits
Anthropic Builds Biology Lab While Expanding AI Drug Ambitions
Semaglutide Helps Children With Obesity, But Raises Caution
